These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16899544)

  • 1. Inhibition of protein aggregation in vitro and in vivo by a natural osmoprotectant.
    Ignatova Z; Gierasch LM
    Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13357-61. PubMed ID: 16899544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proline to the rescue.
    Fisher MT
    Proc Natl Acad Sci U S A; 2006 Sep; 103(36):13265-6. PubMed ID: 16938858
    [No Abstract]   [Full Text] [Related]  

  • 3. Aggregation of a slow-folding mutant of a beta-clam protein proceeds through a monomeric nucleus.
    Ignatova Z; Gierasch LM
    Biochemistry; 2005 May; 44(19):7266-74. PubMed ID: 15882065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-cell aggregation of a polyglutamine-containing chimera is a multistep process initiated by the flanking sequence.
    Ignatova Z; Thakur AK; Wetzel R; Gierasch LM
    J Biol Chem; 2007 Dec; 282(50):36736-43. PubMed ID: 17942400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural osmolytes remodel the aggregation pathway of mutant huntingtin exon 1.
    Borwankar T; Röthlein C; Zhang G; Techen A; Dosche C; Ignatova Z
    Biochemistry; 2011 Mar; 50(12):2048-60. PubMed ID: 21332223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended polyglutamine tracts cause aggregation and structural perturbation of an adjacent beta barrel protein.
    Ignatova Z; Gierasch LM
    J Biol Chem; 2006 May; 281(18):12959-67. PubMed ID: 16524881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of osmolytes on protein folding and aggregation in cells.
    Ignatova Z; Gierasch LM
    Methods Enzymol; 2007; 428():355-72. PubMed ID: 17875429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models.
    Ehrnhoefer DE; Duennwald M; Markovic P; Wacker JL; Engemann S; Roark M; Legleiter J; Marsh JL; Thompson LM; Lindquist S; Muchowski PJ; Wanker EE
    Hum Mol Genet; 2006 Sep; 15(18):2743-51. PubMed ID: 16893904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggregation of truncated GST-HD exon 1 fusion proteins containing normal range and expanded glutamine repeats.
    Hollenbach B; Scherzinger E; Schweiger K; Lurz R; Lehrach H; Wanker EE
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):991-4. PubMed ID: 10434297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. From the test tube to the cell: exploring the folding and aggregation of a beta-clam protein.
    Ignatova Z; Krishnan B; Bombardier JP; Marcelino AM; Hong J; Gierasch LM
    Biopolymers; 2007; 88(2):157-63. PubMed ID: 17206628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases.
    Bodner RA; Outeiro TF; Altmann S; Maxwell MM; Cho SH; Hyman BT; McLean PJ; Young AB; Housman DE; Kazantsev AG
    Proc Natl Acad Sci U S A; 2006 Mar; 103(11):4246-51. PubMed ID: 16537516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-resolution fluorescence of huntingtin reveals growth of globular species into short fibers and coexistence of distinct aggregates.
    Duim WC; Jiang Y; Shen K; Frydman J; Moerner WE
    ACS Chem Biol; 2014 Dec; 9(12):2767-78. PubMed ID: 25330023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replacement of proline with valine does not remove an apparent proline isomerization-dependent folding event in CRABP I.
    Burns-Hamuro LL; Dalessio PM; Ropson IJ
    Protein Sci; 2004 Jun; 13(6):1670-6. PubMed ID: 15152096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a human light chain variable domain (V(L)) intracellular antibody specific for the amino terminus of huntingtin via yeast surface display.
    Colby DW; Garg P; Holden T; Chao G; Webster JM; Messer A; Ingram VM; Wittrup KD
    J Mol Biol; 2004 Sep; 342(3):901-12. PubMed ID: 15342245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The osmophobic effect: natural selection of a thermodynamic force in protein folding.
    Bolen DW; Baskakov IV
    J Mol Biol; 2001 Jul; 310(5):955-63. PubMed ID: 11502004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
    Lecerf JM; Shirley TL; Zhu Q; Kazantsev A; Amersdorfer P; Housman DE; Messer A; Huston JS
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4764-9. PubMed ID: 11296304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid aggregate formation of the huntingtin N-terminal fragment carrying an expanded polyglutamine tract.
    Hazeki N; Nakamura K; Goto J; Kanazawa I
    Biochem Biophys Res Commun; 1999 Mar; 256(2):361-6. PubMed ID: 10079189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide aggregation in neurodegenerative disease.
    Murphy RM
    Annu Rev Biomed Eng; 2002; 4():155-74. PubMed ID: 12117755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologically active molecules that reduce polyglutamine aggregation and toxicity.
    Desai UA; Pallos J; Ma AA; Stockwell BR; Thompson LM; Marsh JL; Diamond MI
    Hum Mol Genet; 2006 Jul; 15(13):2114-24. PubMed ID: 16720620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Derivation of a solubility condition for proteins from an analysis of the competition between folding and aggregation.
    Pechmann S; Vendruscolo M
    Mol Biosyst; 2010 Dec; 6(12):2490-7. PubMed ID: 20957252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.